apixaban_dalteparin
================
Luis Armando Figueroa
2022-09-05

<h4>
Overall Graphs in REML
</h4>
<details>
<summary>
<b>Figure 1 -</b> Odds Ratio of developing Major Bleeding, No Major
Bleeding and Recurrent Venous Thromboembolism Events in the Dalteparin
group vs the Apixaban group
</summary>

![](8%20Output%20Figures/overall_graph_REML-1.svg)<!-- -->

</details>
<h4>
Major bleeding graph in REML
</h4>
<details>
<summary>
<b>Figure 3-</b> Odds Ratio of developing Major Bleeding Events in the
Dalteparin group vs the Apixaban group
</summary>

![](8%20Output%20Figures/major_bleeding_graphs_reml-1.svg)<!-- -->

</details>
<h4>
Major bleeding graph in PM
</h4>
<details>
<summary>
<b>Figure 4-</b> Odds Ratio of developing Major Bleeding Events in the
Dalteparin group vs the Apixaban group
</summary>

![](8%20Output%20Figures/major_bleeding_graphs_pm-1.svg)<!-- -->

</details>
<h4>
No Major bleeding graph in REML
</h4>
<details>
<summary>
<b>Figure 5-</b> Odds Ratio of developing No Major Bleeding Events in
the Dalteparin group vs the Apixaban group
</summary>

![](8%20Output%20Figures/no_major_bleeding_graphs_reml-1.svg)<!-- -->

</details>
<h4>
No Major bleeding graph in PM
</h4>
<details>
<summary>
<b>Figure 6-</b> Odds Ratio of developing No Major Bleeding Events in
the Dalteparin group vs the Apixaban group
</summary>

![](8%20Output%20Figures/no_major_bleeding_graphs_pm-1.svg)<!-- -->

</details>
<h4>
Recurrent Venous Thromboembolism graph in REML
</h4>
<details>
<summary>
<b>Figure 7-</b> Odds Ratio of developing Recurrent Venous
Thromboembolism Events in the Dalteparin group vs the Apixaban group
</summary>

![](8%20Output%20Figures/TE_recurrence_REML-1.svg)<!-- -->

</details>
<h4>
Recurrent Venous Thromboembolism graph in PM
</h4>
<details>
<summary>
<b>Figure 8-</b> Odds Ratio of developing Recurrent Venous
Thromboembolism Events in the Dalteparin group vs the Apixaban group
</summary>

![](8%20Output%20Figures/TE_recurrence_PM-1.svg)<!-- -->

</details>
